share_log

HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $5 Price Target

Benzinga ·  Mar 15 18:27

HC Wainwright & Co. analyst Ed Arce reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $5 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment